- Home
- FMC vs SLNO Comparison
FMC vs SLNO Comparison
Compare FMC & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMC
- SLNO
- Stock Information
- Founded
- FMC 1910
- SLNO 1999
- Country
- FMC United States
- SLNO United States
- Employees
- FMC N/A
- SLNO N/A
- Industry
- FMC Major Chemicals
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- FMC Industrials
- SLNO Health Care
- Exchange
- FMC Nasdaq
- SLNO Nasdaq
- Market Cap
- FMC 4.6B
- SLNO 3.8B
- IPO Year
- FMC N/A
- SLNO 2014
- Fundamental
- Price
- FMC $37.21
- SLNO $69.30
- Analyst Decision
- FMC Buy
- SLNO Strong Buy
- Analyst Count
- FMC 12
- SLNO 10
- Target Price
- FMC $50.58
- SLNO $112.50
- AVG Volume (30 Days)
- FMC 1.6M
- SLNO 1.7M
- Earning Date
- FMC 10-28-2025
- SLNO 08-06-2025
- Dividend Yield
- FMC 6.25%
- SLNO N/A
- EPS Growth
- FMC N/A
- SLNO N/A
- EPS
- FMC 0.80
- SLNO N/A
- Revenue
- FMC $4,131,600,000.00
- SLNO $32,656,999.00
- Revenue This Year
- FMC $0.26
- SLNO N/A
- Revenue Next Year
- FMC $4.72
- SLNO $175.39
- P/E Ratio
- FMC $46.65
- SLNO N/A
- Revenue Growth
- FMC 1.16
- SLNO N/A
- 52 Week Low
- FMC $32.83
- SLNO $41.50
- 52 Week High
- FMC $67.75
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- FMC 40.11
- SLNO 41.17
- Support Level
- FMC $36.26
- SLNO $65.85
- Resistance Level
- FMC $39.99
- SLNO $70.12
- Average True Range (ATR)
- FMC 1.03
- SLNO 2.55
- MACD
- FMC -0.05
- SLNO 0.25
- Stochastic Oscillator
- FMC 22.49
- SLNO 57.45
About FMC FMC Corporation
FMC is a pure-play global crop protection company with a fairly balanced product portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop protection companies and focuses on the development of new products, including biologicals, through its research and development pipeline.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.